Thu, 26 Jan 2012 04:10:55 -0800
US FDA warning: Dr Reddy's to display product risk prominently on Web site
Pharma major Dr Reddy's Laboratories Ltd is redesigning the product Web site of fondaparinux sodium solution following a directive from the US Food and Drug Administration. | Sat, 28 Jan 2012 07:11:06 -0800
Dr Reddy's, USFDA settle product info issue
Pharma major Dr Reddy's Laboratories Ltd said the issue pertaining to its promotional material for fondaparinux sodium for injection, with the US Food and Drug Administration has been closed. | Fri, 03 Feb 2012 03:56:09 -0800
Dr Reddy's Labs Q3 net beats f'casts on U.S. sales
MUMBAI (Reuters) - Dr Reddy's Laboratories , India's No. 2 drugmaker by sales, reported a forecast-beating 88 percent jump in quarterly net profit as sales in its key U.S. market more than doubled. Dr Reddy's , which makes generic molecules and pharmaceutical ingredients, said consolidated net profit rose to 5.13 billion rupees in October-December compared with 2.73 billion rupees a year earlier ... | Thu, 02 Feb 2012 19:18:13 -0800
BSE Sensex seen subdued, Dr. Reddy's watched
MUMBAI (Reuters) - The BSE Sensex could face resistance on Friday as investors take profits after a more than 3 percent rally over the past three days and weighed by caution in Asian markets ahead of the key U.S. jobs data. Dr Reddy's Laboratories Ltd is likely to rise as the company is expected to report a jump in fiscal third-quarter profit helped by launch of new generics in its main United ... | Thu, 26 Jan 2012 10:40:12 -0800
Dr Reddy's in spot with US health regulator again
Dr Reddy's Laboratories has run into trouble with the US health authorities again, this time for not highlighting important risk information on a promotional website for injectable generic fondaprinux sodium, a drug that it launched in the US market recently. | Fri, 27 Jan 2012 03:40:56 -0800
Fondaparinux injection issue resolved with USFDA: Dr Reddy’s
Drug firm Dr Reddy’s Laboratories said it has resolved all issues raised by a division of US health regulator over its promotional material for an anti-coagulant injection. | Fri, 27 Jan 2012 04:39:13 -0800
Anti-coagulant injection issue resolved with USFDA: Dr Reddy's
Drug firm Dr Reddy's Laboratories today said it has resolved all issues raised by a division of US health regulator over its promotional material for an anti-coagulant injection. |
|
|
|
Fri, 03 Feb 2012 11:14:42 GMT
| Sun, 05 Feb 2012 09:02:21 GMT
|
Dr Reddy's US biz bumps up sales and profit growthLivemintDr Reddy's Laboratories Ltd's US generics business contributed to good sales and profit growth during the quarter, and its expectations of further generic launches in the next few quarters should see it contribute to good growth in 2012-13 as well.and more » |
| Fri, 03 Feb 2012 10:17:20 GMT
|
Dr. Reddy's Q3 FY12 Financial ResultsMarketWatch (press release)HYDERABAD, India, Feb 03, 2012 (BUSINESS WIRE) -- Dr. Reddy's Laboratories Ltd. /quotes/zigman/281053/quotes/nls/rdy RDY +0.86% today announced its unaudited consolidated financial results for the quarter ended December 31, 2011 under International ...and more » |
| Fri, 03 Feb 2012 03:12:50 GMT
| Fri, 03 Feb 2012 03:24:14 GMT
|
BSE Sensex seen subdued, Dr. Reddy's watchedReuters IndiaDr Reddy's Laboratories Ltd (REDY.NS) is likely to rise as the company is expected to report a jump in fiscal third-quarter profit helped by launch of new generics in its main United States market. Telecom stocks will be in focus for the second ...and more » |
| Sat, 28 Jan 2012 15:08:44 GMT
| Wed, 08 Feb 2012 13:26:25 GMT
|
|
|
